Mean apparent diffusion coefficient in a single slice may predict tumor response to whole-brain radiation therapy in non-small-cell lung cancer patients with brain metastases

被引:3
|
作者
Zhao, Lihao [1 ]
Zhao, Mengjing [2 ]
Liu, Jinjin [2 ]
Yang, Han [1 ]
Zhou, Xiaojun [2 ]
Wen, Caiyun [2 ]
Li, Gang [1 ]
Duan, Yuxia [2 ]
机构
[1] Wenzhou Med Univ, Dept Chemoradiat Oncol, Affiliated Hosp 1, 2 Fuxue Lane, Wenzhou 325000, Peoples R China
[2] Wenzhou Med Univ, Dept Radiol, Affiliated Hosp 1, South Baixiang St, Wenzhou 325000, Peoples R China
关键词
Diffusion magnetic resonance imaging; Radiotherapy; Brain neoplasms; Carcinoma; non-small-cell lung; Treatment outcome; STEREOTACTIC RADIOSURGERY; SUPPORTIVE CARE; WEIGHTED MRI; RADIOTHERAPY; CHEMORADIOTHERAPY; TOMOGRAPHY; MANAGEMENT; SURVIVAL;
D O I
10.1007/s00330-020-07584-0
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives This study aimed to access the performance of apparent diffusion coefficient (ADC) as a predictor for treatment response to whole-brain radiotherapy (WBRT) in patients with brain metastases (BMs) from non-small-cell lung cancer (NSCLC). Methods A retrospective analysis was conducted of 102 NSCLC patients with BMs who underwent WBRT between 2012 and 2016. Diffusion-weighted MRI were performed pre-WBRT and within 12 weeks after WBRT started. Mean single-plane ADC value of ROIs was evaluated by two radiologists blinded to results of each other. The treatment response rate, intracranial progression-free survival (PFS), and overall survival (OS) were analyzed based on the ADC value and Delta ADC respectively. At last, we used COX and logistic regression to do the multivariate analysis. Results There was good inter-observer agreement of mean ADC value pre-WBRT, post-WBRT, and Delta ADC between the 2 radiologists (Pearson correlation 0.915 [pre-WBRT], 0.950 [post-WBRT], 0.937 [Delta ADC], p < 0.001, for each one). High mean ADC value were related with better response rate (72.2% vs 37.5%, p = 0.001) and iPFS (7.6 vs 6.4 months, p = 0.031). High Delta ADC were related with better response rate (73.6% vs 36.7%, p < 0.001). Multivariate analysis shows that histopathology, BMs number, high ADC value pre-WBRT, and high Delta ADC post-WBRT were related to better treatment response of WBRT, and KPS, BMs number, and low ADC value pre-WBRT increased the risk of developing intracranial relapse. ConclusionsThe mean single-plane ADC value pre-WBRT and Delta ADC post-WBRT were potential predictor for intracranial tumor response to WBRT in NSCLC patients with brain metastases. Key Points ADC value is a potential predictor of intracranial treatment response to WBRT in NSCLC patients with brain metastases. Higher mean ADC value pre-WBRT and.ADC post-WBRT of brain metastases were related to better intracranial tumor response. Prediction of response before WBRT using ADC value can help oncologists to make better therapy plans and avoid missing opportunities for rescue therapy.
引用
收藏
页码:5565 / 5575
页数:11
相关论文
共 50 条
  • [1] Mean apparent diffusion coefficient in a single slice may predict tumor response to whole-brain radiation therapy in non-small-cell lung cancer patients with brain metastases
    Lihao Zhao
    Mengjing Zhao
    Jinjin Liu
    Han Yang
    Xiaojun Zhou
    Caiyun Wen
    Gang Li
    Yuxia Duan
    European Radiology, 2021, 31 : 5565 - 5575
  • [2] Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer
    Yang, R. F.
    Yu, B.
    Zhang, R. Q.
    Wang, X. H.
    Li, C.
    Wang, P.
    Zhang, Y.
    Han, B.
    Gao, X. X.
    Zhang, L.
    Jiang, Z. M.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2018, 51 (01)
  • [3] Whole-Brain Radiation in the Treatment of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer
    Molitoris, Jason K.
    Edelman, Martin J.
    Regine, William F.
    Feigenberg, Steven J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07) : 809 - +
  • [4] Should Erlotinib Be Coadministered With Whole-Brain Radiotherapy in Patients With Brain Metastases and Non-Small-Cell Lung Cancer?
    Chamberlain, Marc C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (25) : 3164 - 3165
  • [5] Whole-Brain Radiation in the Treatment of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer Reply
    Rusthoven, Chad G.
    Doebele, Robert C.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07) : 810 - 811
  • [6] Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non-Small-Cell Lung Cancer
    Welsh, James W.
    Komaki, Ritsuko
    Amini, Arya
    Munsell, Mark F.
    Unger, Wyatt
    Allen, Pamela K.
    Chang, Joe Y.
    Wefel, Jeffrey S.
    McGovern, Susan L.
    Garland, Linda L.
    Chen, Su S.
    Holt, Jamie
    Liao, Zhongxing
    Brown, Paul
    Sulman, Erik
    Heymach, John V.
    Kim, Edward S.
    Stea, Baldassarre
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (07) : 895 - 902
  • [7] Should Erlotinib Be Coadministered With Whole-Brain Radiotherapy in Patients With Brain Metastases and Non-Small-Cell Lung Cancer? Reply
    Welsh, James W.
    McGovern, Susan L.
    Wefel, Jeffrey S.
    Komaki, Ritsuko
    Brown, Paul D.
    Soh, Hendrick E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (25) : 3165 - 3166
  • [8] Response and safety of whole-brain radiotherapy plus temozolomide for patients with brain metastases of non-small-cell lung cancer: A meta-analysis
    Han, Jianguo
    Qiu, Ming
    Su, Li
    Wu, Chong
    Cheng, Si
    Zhao, Zhijun
    Li, Danxia
    Wang, Menghui
    Tao, Wei
    Du, Shiwei
    THORACIC CANCER, 2021, 12 (23) : 3177 - 3183
  • [9] Efficacy of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer
    Koizumi, Tomonobu
    Sasaki, Shigeru
    Sakamoto, Akiyuki
    Kobayashi, Takashi
    ANNALS OF PALLIATIVE MEDICINE, 2013, 2 (03) : 111 - 113
  • [10] Whole-brain radiation therapy in breast cancer patients with brain metastases
    Cyrus Chargari
    François Campana
    Jean-Yves Pierga
    Lionel Védrine
    Damien Ricard
    Sylvestre Le Moulec
    Alain Fourquet
    Youlia M. Kirova
    Nature Reviews Clinical Oncology, 2010, 7 : 632 - 640